Liu J - Search Results

1

In vivo acquired sorafenib-resistant patient-derived tumor model displays alternative angiogenic pathways, multi-drug resistance and chromosome instability.

Hu G, Zhang Y, Ouyang K, Xie F, Fang H, Yang X, Liu K, Wang Z, Tang X, Liu J, Yang L, Jiang Z, Tao W, Zhou H, Zhang L. Hu G, et al. Among authors: liu k, liu j. Oncol Lett. 2018 Sep;16(3):3439-3446. doi: 10.3892/ol.2018.9078. Epub 2018 Jul 4. Oncol Lett. 2018. PMID: 30127946 Free PMC article.

2

Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma.

Yang L, Hu B, Zhang Y, Qiang S, Cai J, Huang W, Gong C, Zhang T, Zhang S, Xu P, Wu X, Liu J. Yang L, et al. Among authors: liu j. Med Oncol. 2015 Apr;32(4):128. doi: 10.1007/s12032-015-0559-1. Epub 2015 Mar 21. Med Oncol. 2015. PMID: 25794490

3

Pan-Cancer Analysis Predicts the Immunological and Prognostic Role of ZC3H12C in KIRC.

Yue Y, Wu Y, Zhao D, Wu B, Wu X, Liu J, Yang L, Shen A. Yue Y, et al. Among authors: liu j. Biomed Res Int. 2022 Jun 26;2022:4541571. doi: 10.1155/2022/4541571. eCollection 2022. Biomed Res Int. 2022. PMID: 35795311 Free PMC article.

4

Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer.

Yang L, Yang S, Liu J, Wang X, Ji J, Cao Y, Lu K, Wang J, Gao Y. Yang L, et al. Among authors: liu j. Exp Mol Pathol. 2014 Apr;96(2):235-41. doi: 10.1016/j.yexmp.2014.02.011. Epub 2014 Mar 3. Exp Mol Pathol. 2014. PMID: 24602846

5

FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma.

Wang Y, Sun M, Liu J, Liu Y, Jiang C, Zhu H, Wang W, Wang Y. Wang Y, et al. Among authors: liu j, liu y. Oncol Lett. 2020 Jan;19(1):795-804. doi: 10.3892/ol.2019.11183. Epub 2019 Dec 4. Oncol Lett. 2020. PMID: 31897196 Free PMC article.

6

Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma.

Zhang Y, Zhang S, Wang X, Liu J, Yang L, He S, Chen L, Huang J. Zhang Y, et al. Among authors: liu j. J Clin Pathol. 2012 Jun;65(6):528-33. doi: 10.1136/jclinpath-2011-200547. Epub 2012 Mar 15. J Clin Pathol. 2012. PMID: 22422806

7

A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma.

Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, Hu Z. Xu Y, et al. Among authors: liu j, liu z, liu l, liu s. Int J Cancer. 2011 Jan 15;128(2):412-7. doi: 10.1002/ijc.25342. Epub 2010 Mar 22. Int J Cancer. 2011. PMID: 20309940

8

IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population.

Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, Liu J, Liu S, Ji G, Shi H, Shen H, Hu Z. Liu L, et al. Among authors: liu z, liu j, liu s. Int J Cancer. 2011 Apr 1;128(7):1692-6. doi: 10.1002/ijc.25488. Epub 2010 Jun 2. Int J Cancer. 2011. PMID: 20521253

9

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.

Hou W, Liu J, Chen P, Wang H, Ye BC, Qiang F. Hou W, et al. Among authors: liu j. Oncol Lett. 2014 Sep;8(3):1249-1254. doi: 10.3892/ol.2014.2253. Epub 2014 Jun 13. Oncol Lett. 2014. PMID: 25120700 Free PMC article.

10

A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE.

Xia Z, Zhao W, Liu J, Zhang J, Pan J, Chen K, Wang L, Zhao H, Chen X. Xia Z, et al. Among authors: liu j. J Oncol. 2022 Sep 28;2022:2704862. doi: 10.1155/2022/2704862. eCollection 2022. J Oncol. 2022. PMID: 36213835 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147,435 results

Search Page

Filters